## Research-question validation

### Phenomenon-vs-method check

**Verdict**: pass

The question asks about a substantive biological relationship between tumor transcriptomic profiles and clinical chemotherapy response, independent of any specific machine learning architecture or computational constraint. The focus is on which gene signatures carry predictive signal, not whether a particular method can achieve a performance threshold.

### Circularity check

**Verdict**: pass

The predictor (gene expression from tumor RNA-seq/microarray) and predicted variable (clinical response to chemotherapy assessed via RECIST or equivalent criteria) derive from independent measurement modalities. One is molecular biology data; the other is clinical outcome assessment. There is no mechanical guarantee of the relationship.

### Triviality check

**Verdict**: concern

While either outcome would be informative, there is substantial prior literature (as shown in related work) demonstrating transcriptomic biomarkers for chemotherapy response in specific cancer types. A positive result confirming known patterns may have limited novelty, though cross-tumor generalizability remains an open question. A null result would be informative if it demonstrates that signatures do not generalize across tumor types, but the expectation of AUC ≥0.75 suggests the positive outcome is somewhat predetermined by domain knowledge.

### Question-narrowing check

**Verdict**: pass

The question names a domain relationship (gene expression → chemotherapy response across tumor types) rather than implementation constraints. It does not fixate on specific algorithmic choices, hardware limits, or runtime budgets.

### Overall verdict

**Verdict**: validated

All four checks pass or present only minor concerns that do not undermine the core research question. The question addresses an open problem in precision oncology (cross-tumor generalizability of transcriptomic biomarkers) with independent predictor and outcome variables. While the related work is extensive, the multi-tumor validation aspect remains a meaningful contribution. [REVISED] Which specific gene‑expression signatures generalize across multiple tumor types to predict chemotherapy response, and what biological pathways underlie this cross‑tumor predictive signal? [/REVISED] Reframing emphasizes the biological mechanism and generalizability question rather than just predictive performance.
